Lynx1 Capital Management Exits Position in Allogene Therapeutics, Inc. (ALLO)

Lynx1 Capital Management LP and Mr. Weston Nichols have filed a Schedule 13G/A with the SEC, indicating that they no longer hold a reportable stake in Allogene Therapeutics, Inc. (ALLO). As of the event date of December 31, 2025, the reporting persons disclosed beneficial ownership of 0 shares of Common Stock, representing 0.0% of the total shares outstanding. This filing serves as an amendment to their previous position and confirms that the reporting persons have ceased to be the beneficial owners of more than five percent of the issuer's class of securities. The reporting persons include Lynx1 Capital Management LP, acting as the investment manager for Lynx1 Master Fund LP, and Mr. Weston Nichols, the sole member of the general partner of the investment manager. The filing was formally submitted on May 15, 2026, and signifies a complete exit from their previously reported position in the South San Francisco-based biotechnology company.